ESSA Pharma Inc (TSX-V: EPI)(NASDAQ: EPIX), a pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported yesterday its financial results for the year ended 30 September 2018.
The company reported a net loss of USD11.6m for the year ended 30 September 2018, compared to a net loss of USD4.5m in the year-ago period.
The firm posted research and development expenditures for the year ended 30 September 2018 at USD4.9m net of grants compared to USD5.7m net of grants for the year ended 30 September 2017.
Cash on hand at 30 September 2018, was USD14.8m, with working capital of USD12.3m, reflecting the aggregate gross proceeds of the completed January 2018 financing, which totalled USD26m.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval